Granules India has informed that it enclosed the press release given by the Company titled ‘Granules Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)’.
The above information is a part of company’s filings submitted to BSE.